Revance Therapeutics Inc (RVNC)

[vinmantoo]

marthambles,

Thanks for the link. I really liked these quotes and it bodes well for RVNC.

Peter McAllister, MD: In my opinion, Daxxify should be a first line therapy in any patient with CD, but it is particularly useful in patients who have had an inadequate response to prior neurotoxins, either because of lack of full efficacy, short duration of effect or tolerability issues.

What questions will we continue to answer over the coming years about daxibotulinumtoxinA’s use in the field?
Atul Patel, MD, MHSA: I think there will be a lot of questions on how Daxxify works in each patient, and in different groups of patients. We will be able to find out if there will be opportunities to treat the patient at different intervals and improve their response to treatment compared to current treatments.

This last one is especially interesting for RVNC shareholders.

Peter McAllister, MD: With increasing clinical use, we will get a better idea of the optimal dose of Daxxify for CD, and how long its duration is (ie time to retreatment) in the real world. We will also look at other therapeutic indications beyond CD.